(10R,11R,15R,16S)-16-{[(2R,4aR,7R,8R,8aS)-7,8-dihydroxy-2-methyl-hexahydro-2H-pyrano[3,2-d][1,3]dioxin-6-yl]oxy}-10-(4-hydroxy-3,5-dimethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.03,7.011,15]hexadeca-1,3(7),8-trien-12-one

• ChemBase ID: 179694
• Molecular Formular: C29H32O13
• Molecular Mass: 588.55658
• Monoisotopic Mass: 588.18429108
• SMILES: [C@@H]12[C@@H](c3c([C@H]([C@H]1C(=O)OC2)c1cc(c(c(c1)OC)O)OC)cc1c(c3)OCO1)OC1[C@@H]([C@H]([C@H]2[C@H](O1)CO[C@H](O2)C)O)O
• Canonical SMILES: COc1cc(cc(c1O)OC)[C@H]1[C@H]2C(=O)OC[C@@H]2[C@@H](c2c1cc1OCOc1c2)OC1O[C@@H]2CO[C@H](O[C@H]2[C@@H]([C@H]1O)O)C
• InChI: InChI=1S/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3/t11-,15+,20-,21-,22+,24-,25-,26-,27-,29?/m1/s1
• InChIKey: VJJPUSNTGOMMGY-PJVTZUROSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: (10R,11R,15R,16S)-16-{[(2R,4aR,7R,8R,8aS)-7,8-dihydroxy-2-methyl-hexahydro-2H-pyrano[3,2-d][1,3]dioxin-6-yl]oxy}-10-(4-hydroxy-3,5-dimethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.0^3,^7.0^1^1,^1^5]hexadeca-1,3(7),8-trien-12-one
• IUPAC Traditional name: (10R,11R,15R,16S)-16-{[(2R,4aR,7R,8R,8aS)-7,8-dihydroxy-2-methyl-hexahydro-2H-pyrano[3,2-d][1,3]dioxin-6-yl]oxy}-10-(4-hydroxy-3,5-dimethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.0^3,^7.0^1^1,^1^5]hexadeca-1,3(7),8-trien-12-one
• Synonyms: Abiposid; Amizide; Citodox; Etopophos; Exitop; Toposar; Vepesid; Vepeside; Vespid; Etoposide

Database IDs

• CAS Number: 33419-42-0
• PubChem SID: 164235604
• PubChem CID: 17571827

CALCULATED PROPERTIES

• Acid pKa: 9.329948
• H Acceptors: 12
• H Donor: 3
• LogD (pH = 5.5): 1.1603667
• LogD (pH = 7.4): 1.155394
• Log P: 1.1604304
• Molar Refractivity: 139.0212 cm^3
• Polarizability: 55.93246 Å^3
• Polar Surface Area: 160.83 Å^2
• Rotatable Bonds: 5
• Lipinski's Rule of Five: false

PROPERTIES

Pharmacology Properties

• Mechanism of Action: DNA topoisomerase II inhibitor

Product Information

• Application(s): Antineoplastic agent

REFERENCES

• Keller-Juslen, C. et al., J. Med. Chem., 1971, 14, 936, (synth, pharmacol)
• Arnold, A.M. et al., Lancet, 1981, 2, 912, (rev)
• Issell, B.F. et al., Etoposide (VP-16): Curr. Status New Dev. [Pap. Symp], (Eds.), Academic Press, 1984, (book)
• Clark, P.I. et al., Clin. Pharmacokinet., 1987, 12, 223, (rev, pharmacol, metab, tox)
• Holthuis, J.J.M. et al., Anal. Profiles Drug Subst., 1989, 18, 121, (rev)
• Sthelin, H.F. et al., Prog. Drug Res., 1989, 33, 169, (rev)
• Sthelin, H.F. et al., Cancer Res., 1991, 51, 5, (rev)
• Semin. Oncol., Suppl. 13, 1992, 19, (rev)
• von Wartburg, A. et al., Chron. Drug Discovery, 1993, 3, 349, (rev)
• Cragg, G. et al., Anticancer Drugs: Antimetabolite Metabolism and Natural Anticancer Agents, (ed. Powis, G.), Pergamon Press, 1994, 364, (rev)
• Negwer, M., Organic-Chemical Drugs and their Synonyms, 7th edn., Akademie-Verlag, 1994, 10960, (synonyms)
• Hainsworth, J.D. et al., Ann. Oncol., 1995, 6, 325, (pharmacol, rev)
• Martindale, The Extra Pharmacopoeia, 32nd edn., Pharmaceutical Press, 1999, 532
• Lewis, R.J., Sax's Dangerous Properties of Industrial Materials, 8th edn., Van Nostrand Reinhold, 1992, EAV500